Business
PetLife Pharmaceuticals Hires InnoVision Therapeutics in Preparation of Vitalzul™ FDA Submission
PetLife Pharmaceuticals Hires InnoVision Therapeutics in Preparation of Vitalzul™ FDA Submission.
About this update from Petlife Pharmaceuticals Inc
[{"type":"text","content":"\n\n HANCOCK, Md., Aug. 25, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the \"Company\"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is pleased to announce the signing of a contract with InnoVision Therapeutics, a major step towards the Center for Veterinary Medicine (CVM)/FDA testing and approval process for Vitalzul™.\n PetLife, having already made a deposit with InnoVision, will immediately begin pre-INAD studies (Investigational New Animal Drug) of Vitalzul™ with InnoVision Therapeutics. InnoVision will work with the company to set up an initial meeting with the CVM to present and refine the regulatory pathway. Experts estimate that it will take between 18-24 months to complete the necessary pre-clinical and clinical studies needed for final FDA review. Vitalzul™ is a new pet oncological treatment, based on Escozine, a blue scorpion venom treatment, which has been used for years to treat humans with cancer in many countries with no signs of toxicity or complications during clinical use. With its ease of administering and significantly lower cost than traditional treatments, PetLife is excited about its new Vitalzul™ product line and expects strong market acceptance. “We are pleased to be working with PetLife Pharmaceuticals. Our great success with Escozine as a therapeutic drug in Humans will be of great benefit to PetLife's Vitalzul™ CVM/FDA process,” stated Dr. Mishra, Managing Director of InnoVision Therapeutics. Dr. Salvagno, CEO of PetLife Pharmaceuticals, comments on the company's progress \"We are delighted that InnoVision is taking PetLife on as a new client. Navigating the CVM/FDA waters is challenging and InnoVision's experience will facilitate smooth travels. Moving our process forward opens up a new frontier in the ongoing oncological battle in pets, providing for less expensive and more effective treatment methods.” Petlife Pharmaceuticals will be presenting Vitalzul™ at the San Francisco Money Show: August 23-25, 2016. Petlife’s 506 Private Placement Memorandum is available only to accredited investors. About InnoVision TherapeuticsInnoVision Therapeutics recognizes the vast potential of early stage Drug discovery and biological research, but realizes that it ...